ReviewCancer2014
Cardiovascular disease in survivors of hematopoietic cell transplantation.
Review in Cancer, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 1 synthesis or guideline pooled it, 87 citations in OpenAlex.
- Cardiovascular events among recipients of hematopoietic stem cell transplantation-A systematic review and meta-analysis.Bone marrow transplantation · 2023Pooled it
- Prediction of cardiovascular disease among hematopoietic cell transplantation survivors.Blood advances · 2018Trial
- Arrhythmias in the setting of hematopoietic cell transplants.Bone marrow transplantation · 2015Trial
- Cardio-Oncological Sequelae of Autologous Stem Cell Transplantation: Role of Clonal Hematopoiesis in Cardiovascular Risk.JACC. Advances · 2026Article
- Endothelial Injury as a Potential Contributor to Cardiovascular Toxicity in Hematologic Malignancies.Diseases (Basel, Switzerland) · 2026Review
- Article
- Impact of Dyslipidemia on Allogeneic Transplantation Outcomes and Cardiovascular Mortality in Patients with Acute Leukemias in the Post-Transplant Cyclophosphamide Era.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Increased Clonal Hematopoiesis in Long-term Survivors of Pediatric Hematopoietic Cell Transplantation.Blood cancer discovery · 2025Article
- Cardiovascular Considerations After Cancer Therapy: Gaps in Evidence andJACC. CardioOncology · 2025Review
- Clonal Hematopoiesis and Risk of Heart Failure After Autologous Hematopoietic Cell Transplantation for Lymphoma.JACC. CardioOncology · 2025Article
- Article
- Cardiac-output response to exercise after allogeneic hematopoietic stem cell transplantation: a case report with a 2-year follow-up.International cancer conference journal · 2024Article
- Risk of atrial fibrillation in patients with multiple myeloma: what is known and directions for future study.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2024Review
- Peripheral Ischemia Imprints Epigenetic Changes in Hematopoietic Stem Cells to Propagate Inflammation and Atherosclerosis.Arteriosclerosis, thrombosis, and vascular biology · 2023Article
- Reduced cardiovascular reserve capacity in long-term allogeneic stem cell transplant survivors.Scientific reports · 2023Article
- Article
- Cardiovascular Complications in Hematopoietic Stem Cell Transplanted Patients.Journal of personalized medicine · 2022Review
- Long-Term Health Effects of Curative Therapies on Heart, Lungs, and Kidneys for Individuals with Sickle Cell Disease Compared to Those with Hematologic Malignancies.Journal of clinical medicine · 2022Review
- Article
- Sex-Specific Cardiovascular Risks of Cancer and Its Therapies.Circulation research · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Hematopoietic cell transplantation (HCT) is increasingly offered as a curative option for many patients with hematologic malignancies. Improvements in HCT strategies and supportive care have resulted in a growing number of long-term survivors. However, these survivors are at an increased risk of developing long-term debilitating chronic health conditions, including premature cardiovascular disease. These complications are more common than in the general population, and there are well-described associations between therapeutic exposures, traditional cardiovascular risk factors, and subsequent cardiovascular disease risk. The authors present herein an overview of the current state of knowledge regarding pathogenesis and risk factors for some of the more commonly occurring cardiovascular complications after HCT, highlighting existing surveillance recommendations and future directions for research to minimize cardiovascular morbidity in these survivors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.